Pimozide/Strong CYP2D6 Inhibitors
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your body processes pimozide.
What might happen:
The amount of pimozide in your blood may increase, which may increase your risk of developing an irregular heartbeat, which may be life threatening.
What you should do about this interaction:
Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. Let your doctor know right away if you notice and irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this drug interaction and may be monitoring you for it. Do not stop start, or change the dosage of any medicine before checking with them first.
1.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
2.Orap (pimozide) US prescribing information. Gate Pharmaceuticals August, 2011.
3.Paxil (paroxetine hydrochloride) US prescribing information. GlaxoSmithKline December, 2012.
4.Pexeva (paroxetine mesylate) US prescribing information. Noven Therapeutics, LLC December, 2012.
5.Prozac (fluoxetine hydrochloride) US prescribing information. Eli Lilly and Company January, 2013.
6.Sarafem (fluoxetine hydrochloride) US prescribing information. Warner Chilcott April, 2009.
7.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
8.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.